RALEIGH — Inceptor Bio, a group supporting biotech companies “from concept to commercialization,” has added $500,000 to its coffers, bringing the total funds raised to $3.2 million since May, according to a recent securities filing.
The Raleigh-based firm identifies, incubates and accelerates novel technologies to advance progress for curing cancer and neurodegenerative diseases.
Six investors contributed to the round, which kicked off on April 20.
The filing noted the issuer’s identity as the Kineticos Disruptor Fund, which was launched earlier this year by Kineticos.
Founded in 2007 by UNC-Chapel Hill grad Shailesh Maingi, Kineticos supports biopharmaceutical and precision medicine firms.
According to Maingi’s LinkedIn account, it initially concentrated on strategy, licensing, and market access support for Precision Medicine firms.
In 2012, it launched its biopharma practice and four years later, its internal think tank, The Kineticos Research Institute, which includes the Biotech CEO Confidence Index, The Disruptor26 podcast series, white papers, and other relevant content.
